Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Pharmacol Ther. 2018 Jun 30;192:1–19. doi: 10.1016/j.pharmthera.2018.06.015

Figure 5. Epoxyeicosatrienoic acid (EET) analogs and soluble epoxide hydrolase (sEH) inhibitors combat cardiovascular diseases.

Figure 5

EET analogs and sEH inhibitors decrease cardiac cell inflammation and oxidative stress. Cardiac cell signaling mechanisms leading to fibrosis, endoplasmic reticulum stress and hypertrophy are combated by EET analogs and sEH inhibitors to opposed heart diseases.